Rachel Kaye

Dr. Rachel Kaye


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2017 in Toxins
Verified
Journal Article
Open access
PDF file
RKRachel Kaye
Rachel Kaye
ABAndrew Blitzer
Andrew Blitzer
Botulinum neurotoxin (BoNT) has existed for thousands of years; however, it was not medically utilized until investigations into its therapeutic use began in sincerity during the late 1970s and 1980s. This, coupled with the reclassification of spasmodic dysphonia as a focal dystonia, led to the use of chemodenervation for this disorder, which has since become a refined technique. Indeed, due to its safety and efficacy, BoNT has been investigated in multiple neurolaryngology disorders, including spasmodic dysphonia, vocal tremor, and muscle tension dysphonia. BoNT has been shown to be a useful and safe adjunct in the treatment for these disorders and may reduce or eliminate oral pharmacotherapy and/or prevent the need for a surgical intervention. We present the historical background, development, proposed mechanisms of action, uses, and techniques for administering BoNT for laryngeal disorders, with a particular focus on spasmodic dysphonia.

15 October 2024 in OTO Open
Verified
Journal Article
Open access
RMRaj Malhotra
Raj Malhotra
HKHamza Khan
Hamza Khan
SZSydney Zaransky
Sydney Zaransky
JCJoseph Celidonio
Joseph Celidonio
KYKenneth Yan
Kenneth Yan
RKRachel Kaye
Rachel Kaye
Objective: Retrograde cricopharyngeal dysfunction (R‐CPD) is a syndrome with rapidly increasing awareness since being first described in March 2019. As such, few cases of R‐CPD are currently reported in the literature. The goal of this study is to provide a comprehensive systematic review of the available literature on R‐CPD, including patient characteristics, diagnosis, and management.Data Sources: PubMed, Scopus, EMBASE.Review Methods: A systematic review of the available English literature was conducted using the data sources PubMed, Scopus, and EMBASE. Studies with original data of patients experiencing classic symptoms of R‐CPD were included. Independent abstract screening followed by full‐text screening was performed to assess study eligibility. Data extraction of patient demographics, symptoms, treatment, and follow‐up were subsequently performed.Results: Common presentations of R‐CPD include abelchia (100%), abdominal bloating (83%), and gurgling noises (75%). 554 (86.9%) patients had improved symptoms after initial treatment with BTX. The most common initial dose was 50 units in 204 (37.3%) patients. Subsequent BTX injections resolved symptoms in 40 (80%) patients. Six patients ultimately received CP myotomy for recurrent symptoms, resulting in long‐term resolution in 4 (67%) patients.Conclusion: R‐CPD is a newly recognized syndrome with effective treatment options including botulinum toxin injections and cricopharyngeal myotomy, where appropriate. Diagnostic modalities including esophageal manometry may aid in the initial work up of R‐CPD, however further studies are required to assess its diagnostic utility.

19 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
JWJulie Walsh-Messinger
Julie Walsh-Messinger
SKSahar Kaouk
Sahar Kaouk
HMHannah Manis
Hannah Manis
RKRachel Kaye
Rachel Kaye
GCGuillermo Cecchi
Guillermo Cecchi
DMDolores Malaspina
Dolores Malaspina
Aerosol droplets have emerged as the primary mode of SARS-Cov-2 transmission and can be spread by infectious asymptomatic/pre-symptomatic persons rendering indicators of latent viral infection essential. Olfactory impairment is now a recognized symptom of COVID-19 and is rapidly becoming one of the most reliable indicators of the disease. We compared olfaction data from asymptomatic students, who were assessed as SARS-CoV-2 was unknowingly spreading locally, to students tested prior to the arrival of the virus. This study was naturalistic by design as testing occurred in the context of four research studies, all of which used the same inclusion/exclusion criteria and the same protocol to objectively assess odor detection, identification, and hedonics with physiological tests. Data from students (Cohort II; N=22) with probable SARS-CoV-2 exposure were compared to students tested just prior to local virus transmission (Cohort I; N=25), and a normative sample of students assessed over the previous four years (N=272). Students in Cohort II demonstrated significantly reduced odor detection sensitivity compared to students in Cohort I (t=2.60; P=.01; d=0.77; CI, 0.17, 1.36), with a distribution skewed towards reduced detection sensitivity (D=0.38; P=.005). Categorically, the exposed group was significantly more likely to have hyposmia (OR=7.74; CI, 3.1, 19.40), particularly the subgroup assessed in the final week before campus closure (OR=13.61; CI, 3.40, 35.66;). The exposed cohort also rated odors as less unpleasant (P<.001, CLES=0.77). A limitation of our study is that participants were not tested for COVID-19 as testing was unavailable in the area. Objective measures of olfaction may detect olfactory impairment in asymptomatic persons who are otherwise unaware of smell loss. The development of cost-effective, objective olfaction tests that could be self-administered regularly could aid in early detection of SARS-CoV-2 exposure, which is vital to combatting this pandemic.

12 September 2018 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
AZAlbert H. Zhou
Albert H. Zhou
VPVaresh R. Patel
Varesh R. Patel
WHWayne D. Hsueh
Wayne D. Hsueh
BPBoris Paskhover
Boris Paskhover
RKRachel Kaye
Rachel Kaye

8 September 2022 in The Laryngoscope
Verified
Journal Article
Closed access
ACAngela Cao
Angela Cao
PSPooja Swami
Pooja Swami
RKRachel Kaye
Rachel Kaye
TGTodd Goldstein
Todd Goldstein
DGDaniel A. Grande
Daniel A. Grande
LSLee P. Smith
Lee P. Smith

3 July 2024 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
JCJoseph Celidonio
Joseph Celidonio
RBRohini Bahethi
Rohini Bahethi
RMRaj Malhotra
Raj Malhotra
SSSuchitra Sangappa
Suchitra Sangappa
RKRachel Kaye
Rachel Kaye
Objectives: Rhinoscleroma is classically described as a chronic granulomatous disease caused by Klebsiella rhinoscleromatis which primarily affects the nose and nasopharynx. When present, tracheal manifestations will be seen late in the disease course rather than on initial presentation. We describe a rare case of nonendemic rhinoscleroma that presented with tracheal lesions as an initial manifestation of disease.Methods: Case report and literature review.Results: An 88‐year‐old male presented with longstanding dysphonia. Flexible laryngoscopy demonstrated a septal perforation and diffuse glottic lesions. CT neck demonstrated a nonobstructive polypoid tracheal lesion and mucosal thickening of the paranasal sinuses. Biopsy confirmed an atypical lympho‐histiocytic proliferation and microorganisms within macrophages on Grocott methenamine silver and Steiner stains consistent with rhinoscleroma. He was referred for rheumatology and pulmonology consultation.Conclusion: Systemic diseases rarely affect the trachea, and even less frequently is a tracheal lesion identified as the initial manifestation of disease. The most common systemic diseases that affect the trachea include relapsing polychondritis, granulomatosis with polyangiitis, amyloidosis, and inflammatory bowel disease. The literature surrounding nasolaryngotracheal rhinoscleroma is limited, especially in nonendemic areas. It is necessary to include unusual etiologies of airway lesions in the differential diagnosis, which warrants comprehensive airway evaluation including biopsy.Level of Evidence: 4.